Gene Therapy's Future Can Be NAV-igated Alone, REGENXBIO CEO Says
This article was originally published in Scrip
Having netted $148m in its September initial public offering, REGENXBIO, Inc. is moving toward the clinic with its first two gene therapy candidates and believes it – and its licensees – are positioned to succeed in gene therapy where earlier attempts failed. Coming out of a "quiet period" after its IPO, which sold 7.2 million shares at $22 apiece, REGENXBIO CEO Kenneth Mills talked to Scrip's sister publication "The Pink Sheet" DAILY about his company's plans and strategies, as well as why its novel adeno-associated virus (NAV) vectors might be more viable than the first iteration of AAV-based therapies.
You may also be interested in...
Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.